Primary signet-ring cell carcinoma of the pancreas diagnosed by endoscopic retrograde pancreatic duct biopsy: a case report with an immunohistochemical study

Fig. 1 Endoscopic retrograde cholangiopancreatography in a patient with primary signet-ring cell carcinoma of the pancreas. The main pancreatic ducts and common bile duct in the pancreatic head portion show irregular occluded contours.

Fig. 2 Pancreatic biopsy taken during endoscopic retrograde cholangiopancreatography. The biopsy shows pancreatic signet-ring cell carcinoma. Hematoxylin and eosin, $\times 100$.

Primary signet-ring cell carcinoma (SRCC) of the pancreas is extremely rare [1]; only three cases have been reported in the literature [2–4].

A 61-year-old man presented with abdominal pain. Laboratory blood testing revealed hyperamylasemia (626 IU/L). Tumor marker concentrations were within normal ranges. Upper gastrointestinal endoscopy showed no significant changes, as did CT including the pancreas. Pancreatitis was suspected and the patient underwent endoscopic retrograde cholangio-

pancreatography (ERCP) and endoscopic retrograde pancreatic duct biopsy. The ERCP showed irregular occluded pancreatic ducts at the pancreatic head (Fig. 1). The pancreatic duct biopsy revealed SRCC (Fig. 2).

The carcinoma cells were positive for mucins on alcian blue/periodic acid–Schiff staining. An immunohistochemical study was performed using Dako's EnVision method, as previously described [5,6]. The SRCC cells were positive for cytokeratin AE1/3, cytokeratin CAM5.2, cytokeratin

tin 7 (CK7), cytokeratin 8 (CK8), cytokeratin 18 (CK18) (Fig. 3a), cytokeratin 19 (CK19), carcinoembryonic antigen (CEA) (Fig. 3b), epithelial membrane antigen (EMA), p53, Ki67 (labeling = 15%), mucin 1 (MUC1), and mucin 5AC (MUC5AC) (Fig. 3c).

They were negative for cytokeratin 34BE12, cytokeratin 5/6 (CK5/6), cytokeratin 14 (CK14), cytokeratin 20 (CK20), p63, carbohydrate antigen 19–9 (CA19–9), vimentin, thyroid transcription factor 1 (TTF-1), homeobox protein CDX-2 (CDX2), mucin 2 (MUC2), and mucin 6 (MUC6). The patient underwent pancreatoduodenectomy at another hospital. The resected surgical specimen showed infiltrating SRCC at the pancreatic head. The patient is now alive 6 months after the operation.

The present case is the first one of primary SRCC diagnosed by endoscopic retrograde biopsy of the pancreatic duct. Thus, this procedure may be stated to be useful in the diagnosis of pancreatic SRCC when tumor cells have penetrated the lumen of the pancreatic duct. The present case is also the first one in which the immunoprofile of pancreatic SRCC was extensively examined. The cytokeratin profile has been demonstrated. The expression of CK7, CK8, CK18, and CK19 – pancreatic cytokeratins – is compatible with the cytokeratin profile of pancreatic ductal carcinoma [7,8]. The cytokeratin profile indicates that high-molecular-weight cytokeratins (CK34BE12 and CK5/6), CK14, and CK20 were absent from pancreatic SRCC. Pancytokeratins (AE1/3 and CAM5.2) and EMA were present. The positive p53 result and relatively high Ki67 labeling index show p53 mutations and high proliferative activity. The positive expression of CEA indicates the malignant nature of the tumor [2]. However, the serum CEA level was normal. The MUC apomucin profile is compatible with the pancreatic duct MUC mucin profile [7,8]. The negative results for expression of p63, CA19–9, vimentin, TTF-1, and CDX2 indicate that these substances are absent in pancreatic SRCC.

In conclusion, the author has presented an extremely rare case of primary pancreatic SRCC diagnosed by endoscopic retrograde biopsy of the pancreatic duct. In addition, he performed an extensive immunohistochemical study of primary pancreatic SRCC.

Endoscopy_UCTN_Code_CCL_1AZ_2AB

Competing interests: None

Fig. 3 The pancreatic signet-ring cell carcinoma cells stain positive for cytokeratin 18 (a), carcinoembryonic antigen (b), and mucin 5AC (c). Immunostaining, $\times 100$.

T. Terada

Department of Pathology, Shizuoka City Shimizu Hospital, Shizuoka, Japan

References

- 1 Fukushima N, Hruban RH, Kato Y et al. Ductal adenocarcinoma variants and mixed tumor of the pancreas. In: Bosman FT, Carneiro F, Hruban RH et al. eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010: 292–295
- 2 Tracey KJ, O'Brien MJ, Williams LF et al. Signet ring cell carcinoma of the pancreas, a rare variant with very high CEA values; immunohistologic comparison with adenocarcinoma. *Dig Dis Sci* 1984; 29: 573–576
- 3 Chow LT, Chow WH. Signet-ring mucinous adenocarcinoma of the pancreas. *Chin Med Sci J* 1994; 3: 176–178
- 4 McAuthur CP, Fiorella R, Saran BM. Rare primary signet ring cell carcinoma of the pancreas. *Mol Med* 1995; 92: 298–302
- 5 Terada T, Kawaguchi M, Furukawa K, Sekido Y, Osamura Y. Minute mixed ductal-endocrine carcinoma of the pancreas with predominant intraductal growth. *Pathol Int* 2002; 52: 40–746
- 6 Terada T, Kawaguchi M. Primary clear cell adenocarcinoma of the peritoneum. *Tohoku J Exp Med* 2005; 206: 271–275
- 7 Hruban RH, Kloppel G, Boffetta P et al. Ductal adenocarcinoma of the pancreas. In: Bosman FT, Carneiro F, Hruban RH et al. eds. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010: 281–291
- 8 Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. *J Pathol* 1996; 180: 160–165

Bibliography

DOI 10.1055/s-0030-1256934

Endoscopy 2012; 44: E141–E142

© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author

T. Terada, MD, PhD

Department of Pathology
Shizuoka City Shimizu Hospital
Miyakami 1231 Shimizu-Ku
Shizuoka 424-8636
Japan
Fax: +81-54-3341173
piyo0111jp@yahoo.co.jp